Novo Nordisk increased operating profit by 27% in 2010

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Clinical Trial Supplies Market Worth $8.18 Billion by 2030

The market for clinical trial supplies is about to...

AI in Genomics Market – Setting Pace for Vast Genomic Data

There is no shred of doubt that artificial intelligence...

Recyclable Pharma Packaging: Market To Hit $335B By 2032

There will be a lot more demand for recyclable...

Key Trends Shaping Indian Pharmaceutical Packaging Market

The pharmaceutical business has a major economic influence on...

Organic sales growth of 19% driven by Victoza®, NovoRapid® and Levemir® Sales increased by 19% in Danish kroner and by 13% in local currencies. Gross margin improved by 1.2 percentage points in Danish kroner to 80.8% in 2010, reflecting a favourable product mix development and a positive currency impact. Reported operating profit increased by 27% to DKK 18,891 million. Measured in local currencies, operating profit increased by approximately 16%. Net profit increased by 34% to DKK 14,403 million. Earnings per share (diluted) increased by 38% to DKK 24.60.

The phase 3a programme for Degludec and DegludecPlus has now been completed. In the largest trial, the one-year trial comparing Degludec and insulin glargine when added to oral anti-diabetic therapy in type 2 diabetes, Degludec met the primary endpoint of non-inferior glucose control while reducing nocturnal hypoglycaemia by more than 35% compared to insulin glargine.

For 2011, sales growth measured in local currencies is expected to be 8-10%, and operating profit growth measured in local currencies is expected to be around 15%.

In 2010, Novo Nordisk reached the four long-term financial targets announced in the annual report for 2008. Consequently, three of the four targets have been increased while the core target of 15% annual operating profit growth has been maintained.

At the Annual General Meeting on 23 March 2011, the Board of Directors will propose a 33% increase in dividend to DKK 10 per share. The Board of Directors has furthermore decided to initiate a new share repurchase programme of DKK 10 billion in 2011.

Lars Rebien Sørensen, president and CEO: “2010 was a very good year for Novo Nordisk with strong organic sales growth driven by the modern insulins and Victoza®. We expect continued sales growth from these products and are encouraged by the results from the phase 3 programme with our new generation insulins.”

Latest stories

Related stories

Clinical Trial Supplies Market Worth $8.18 Billion by 2030

The market for clinical trial supplies is about to...

AI in Genomics Market – Setting Pace for Vast Genomic Data

There is no shred of doubt that artificial intelligence...

Recyclable Pharma Packaging: Market To Hit $335B By 2032

There will be a lot more demand for recyclable...

Key Trends Shaping Indian Pharmaceutical Packaging Market

The pharmaceutical business has a major economic influence on...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back